IC-COVID-19: Infection Control for Severe Acute Respiratory Syndrome Coronavirus 2

NMC Specialty Hospital (Other)
Overall Status
CT.gov ID

Study Details

Study Description

Brief Summary

The investigators aim to develop expert consensus statements on infection control management of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in intensive care units (ICU).

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The COVID-19 pandemic has resulted in a considerable change in the infection control protocols in the hospitals, especially ICU. The ICU management of these patients requires robust infection control measures in order to prevent cross-transmission of SARS-CoV-2 (to healthcare workers (HCWs) and other patients) and hospital acquired bacterial or fungal infections. The understanding of epidemiological characteristics of SARS-CoV-2 and pathophysiology of coronavirus disease 2019 (COVID-19) along with evidence on transmission of SARS-COV-2 in controlled healthcare-setting is still evolving. The mode of transmission of SARS-CoV-2 is airborne, through droplets or fomites. Respiratory interventions performed in these patients in ICU, such as non-invasive ventilation, high flow nasal oxygen or tracheal intubation are considered to be aerosol generating procedures and may lead to airborne transmission of SARS-CoV-2. In the absence of the robust evidence, there are no specific recommendations available on infection control of SARS-CoV-2 in ICU.

    The objective of this study is to achieve consensus statements on the infection control management of SARS-CoV-2 in ICU.

    The whole process of this study will be done in the form of three-four rounds of Google Forms-based Delphi surveys. The survey questionnaire, will be prepared by the investigators after systematic search of available literature and concern areas in the infection control of SARS-CoV-2 in ICU. The objective is to achieve consensus statements on the infection control management of SARS-CoV-2 in ICU.

    The survey questionnaire is divided into five sections: 1.Design and engineering 2.Health-care workers and visitors 3. Personal protective equipment 4. Patient and procedures 5. Disinfection and sterilisation.

    The majority of these questionnaire statements are to be rated on Likert scale and others have multiple choices. The participating experts comments and feedback will be collected through comment section after each question in round one. All the subsequent surveys will be iterative and the experts can give their opinion in each round using either open text or directly to steering group of investigators.

    Study Design

    Study Type:
    Actual Enrollment :
    35 participants
    Observational Model:
    Time Perspective:
    Official Title:
    Expert Statements on Infection Control in Intensive Care Unit for Severe Acute Respiratory Syndrome Coronavirus 2
    Actual Study Start Date :
    Mar 29, 2021
    Actual Primary Completion Date :
    Apr 25, 2021
    Actual Study Completion Date :
    May 1, 2021

    Outcome Measures

    Primary Outcome Measures

    1. Consensus using participating experts opinions. [30 days]

      For statements with responses on an ordinal 7-point Likert scale, 'agreement' is defined as a score of 5-7, 'neutral' by a score of 4 and 'disagreement' by a score of 1-3. Consensus is defined as achieved when >70% of the experts voted for a given option in Likert scale statement. Median and interquartile range (IQR) were used to describe the central tendency and dispersion of responses. For multiple-choice questions (MCQs), consensus is defined as achieved if >80% of the experts voted for a particular option. Stability in the responses will be assessed from round two onwards. Stability will be assessed between the two concluding rounds for each statement, using the non-parametric chi square (χ2) test. p < 0·05 is considered as a significant variation or unstable.

    Eligibility Criteria


    Ages Eligible for Study:
    25 Years to 70 Years
    Sexes Eligible for Study:
    Accepts Healthy Volunteers:

    Inclusion criteria for participants Health care professionals involved in the management of COVID-19 patients with publications and expertise in infectious disease, infection control, sepsis, respiratory failure or public health.

    Exclusion Criteria:
    • Those who do not accept the invitation or not meeting any of the inclusion criteria.

    Contacts and Locations


    Site City State Country Postal Code
    1 NMC Specialty Hospital Dubai United Arab Emirates 7832

    Sponsors and Collaborators

    • NMC Specialty Hospital


    • Principal Investigator: Sheila Myatra, MD, Tata Memorial Hospital, Mumbai, India

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:


    Responsible Party:
    Prashant Nasa, Head Critical Care Medicine, NMC Specialty Hospital
    ClinicalTrials.gov Identifier:
    Other Study ID Numbers:
    • NMCSpecialtyH
    First Posted:
    Dec 14, 2020
    Last Update Posted:
    May 11, 2021
    Last Verified:
    May 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    Studies a U.S. FDA-regulated Device Product:
    Keywords provided by Prashant Nasa, Head Critical Care Medicine, NMC Specialty Hospital
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 11, 2021